Streetbeat News

Revenues

VRA

Vera Bradley projects its FY25 revenue to be between $460M and $480M, which is below the estimated $490.32M. Additionally, the company forecasts EPS to range from $0.54 to $0.62, also falling short of the expected $0.7.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:08 pm

PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) announced the publication of preclinical research and the grant of a U.S. patent for its Infectimune® platform, demonstrating significant advancements in influenza vaccine development. The research showed Infectimune®'s ability to improve the quantity and quality of CD4 T cells, positioning it as a leading candidate for next-generation vaccines. The USPTO granted Patent Number 11,904,015 for vaccine compositions using Infectimune®, enhancing PDS Biotech's intellectual property portfolio.

Portfolio Pulse from Happy Mohamed

March 13, 2024 | 12:04 pm

WEST

In the latest quarter, 4 analysts provided mixed ratings for Westrock Coffee (NASDAQ:WEST), with an average 12-month price target of $12.5, reflecting a 13.64% increase from the previous target. The company's financial overview shows a revenue decline of -4.64% for the last 3 months as of September 30, 2023, but strong profitability indicators such as a net margin of 5.83%, ROE of 22.88%, and ROA of 1.49%. However, its debt-to-equity ratio of 2.12 suggests higher financial risk.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 12:01 pm

OCUL

Ocular Therapeutix (NASDAQ:OCUL) has received mixed analyst ratings over the past three months, with a trend towards more bullish perspectives. The average 12-month price target for OCUL has been raised to $15.33, indicating a 46.0% increase from the previous target of $10.50. Analysts from firms like HC Wainwright & Co., TD Cowen, JMP Securities, Piper Sandler, and B of A Securities have adjusted their ratings and price targets, reflecting optimism about the company's future performance. Ocular Therapeutix, a biotechnology firm focusing on eye disease therapies, shows a positive revenue trend but struggles with profitability and efficiency metrics compared to industry averages.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 12:01 pm

MC

Four financial analysts have recently updated their ratings on Moelis & Co (NYSE:MC), with three maintaining a neutral stance and one expressing a bearish view. The average 12-month price target for MC has been raised to $54.5, reflecting a 16.78% increase from the previous target of $46.67. Analysts from Goldman Sachs, JP Morgan, and Keefe, Bruyette & Woods have adjusted their price targets, indicating a mixed outlook on the company's financial performance. Despite a revenue growth of 3.71% as of December 31, 2023, Moelis faces challenges in market capitalization, net margin, ROE, and ROA, positioning it below industry averages.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 12:01 pm

ADTH

AdTheorent Holding (NASDAQ:ADTH) has been analyzed by 4 analysts, showing a positive shift in sentiment with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target has increased by 26.86% to $4.44, with a high estimate of $7.00 and a low of $3.00. The company's financial overview highlights a market cap below industry averages, a revenue growth rate of 8.8%, and challenges in profitability and asset utilization. AdTheorent focuses on performance-first, privacy-forward digital advertising, primarily in the US.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 12:00 pm

RCL

Royal Caribbean Gr (NYSE:RCL) has received diverse analyst ratings over the last three months, with a total of 10 analysts offering evaluations ranging from bullish to bearish. The average 12-month price target for RCL is $151.8, marking an 11.16% increase from the previous target of $136.56. Analysts have adjusted their ratings and price targets based on market conditions and company performance, reflecting a positive outlook on RCL's financial health, including a revenue growth rate of 27.96% and an impressive net margin of 8.32%. Royal Caribbean operates 65 ships across five brands and has shown substantial market capitalization and financial performance above industry averages.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 12:00 pm

ADDYY

Adidas AG (OTC:ADDYY) reported a 2% decline in currency-neutral revenues for Q4 FY23, with a notable 8% decline in euro terms due to unfavorable currency movements and the absence of Yeezy business. Despite these challenges, footwear sales rose 8%, driven by growth in Originals and Skateboarding. The company faced a 21% sales decrease in North America but saw a 37% increase in Greater China. Adidas anticipates mid-single-digit sales growth in FY24, despite inventory and currency challenges, and expects an operating profit of around €500 million.

Portfolio Pulse from Shivani Kumaresan

March 13, 2024 | 11:54 am

WOW

WideOpenWest (WOW) forecasts Q1 total revenue to be between $159M-$162M, falling short of the estimated $164.93M. The company also anticipates its adjusted EBITDA to range from $64M-$67M.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:09 am

SLN

Silence Therapeutics reported a 2023 revenue of £25.4M, driven by collaboration agreements with AstraZeneca, Hansoh, and Mallinckrodt. Despite an increase in revenue, the company experienced a net loss of £43.3M, with a cash balance of £54.0M by year-end. R&D expenses rose to £44.0M due to additional clinical studies and manufacturing activities.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:09 am